<DOC>
	<DOCNO>NCT01088906</DOCNO>
	<brief_summary>This study pemetrexed disodium plus cisplatin first-line therapy patient advance non-squamous cell lung cancer . This phase IIA pharmacogenomic trial .</brief_summary>
	<brief_title>Study Pemetrexed Plus Cisplatin First-line Therapy Patients With Advanced Non-squamous NSCLC</brief_title>
	<detailed_description>This non-randomized , phase IIA pharmacogenomic , open label , uncontrolled , efficacy study patient advance non-squamous cell lung cancer first line therapy .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic cytologic diagnosis nonsquamous NSCLC , amenable curative treatment surgery radiation therapy . This population encompass advanced stage patient select stage IIIB ( pleural pericardial effusion ) stage IV disease . Histologic cytologic documentation recurrence require patient previously completely resect progressive disease . Tissue must available generate apply genomics predictor . If obtain time diagnosis , subject must consent another biopsy . If patient prior radiation therapy , tissue biopsy genomics analysis must outside radiation field . At least one , nonradiated , measurable lesion RECIST criterion . ECOG performance status 0 1 No prior chemotherapy , biologic target therapy malignancy . Prior radiation therapy permit â‰¥1 week since completion radiation treatment . Radiation must &lt; 25 % bone marrow reserve . Age great 18 year . No previous concomitant malignancy past 5 year surgical management carcinoma situ cervix basal cell squamous cell carcinoma skin . No serious medical psychiatric illness . Signed informed consent . Females childbearing potential ( surgically sterilize menarche 1 year post menopause ) must test negative pregnancy within 7 day prior time enrollment base serum pregnancy test . Both sexually active male female reproductive potential must agree use reliable method birth control , determine patient health care team , study 3 month follow last dose study drug . Required laboratory data within two week enrollment : 1 . ANC AGC great 1500 per uL 2 . Platelets great 100,000 per uL 3 . Total bilirubin less 1.5mg/dL 4 . Creatinine clearance great equal 45 ml/min . 5 . SGOT/SGPT le equal 3x/ULN except presence know hepatic metastasis may 5x ULN . Patients squamous cell NSCLC . Treatment within last 30 day drug receive regulatory approval indication time study entry . Concurrent administration antitumor therapy . Inability comply protocol study procedure . Active infection require IV antibiotic , antifungal antiviral agent , opinion investigator would compromise patient 's ability tolerate therapy . Documented symptomatic untreated central nervous system ( CNS ) metastases ( except adequately treat stable least 2 week ) . Major surgery within 2 week study serious concomitant systemic disorder , opinion investigator , would compromise safety patient compromise patient 's ability complete study . Myocardial infarction occur less 6 month inclusion , know uncontrolled arrhythmia , symptomatic angina pectoris , active ischemia cardiac failure control medication . Have peripheral neuropathy CTCAE Grade 1 high Contraindications corticosteroid . Inability unwillingness take folic acid vitamin B12 supplementation . Unwillingness stop take herbal supplement study . Presence clinically significant thirdspace fluid collection ( example , ascites pleural effusion ) control drainage procedure prior study entry throughout study enrollment distribution pemetrexed fluid space fully understood . Recent ( within 30 day enrollment ) concurrent yellow fever vaccination . Have prior know allergic/hypersensitivity reaction component study treatment Inability discontinue administration aspirin dose great 1300 mg/day nonsteroidal antiinflammatory agent 2 day , day , 2 day dose pemetrexed ( 5 day longacting agent piroxicam ) . Female patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Phalcis</keyword>
	<keyword>BRCA1</keyword>
	<keyword>RAP80</keyword>
	<keyword>TS</keyword>
	<keyword>First line</keyword>
	<keyword>Non-squamous</keyword>
</DOC>